利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

67 条记录 (耗时 0.035 秒)

    Biochemical markers for CVD risk assessment
    53.
    发明授权
    Biochemical markers for CVD risk assessment 有权
    CVD风险评估的生化标志物

    公开(公告)号：US09359633B2

    公开(公告)日：2016-06-07

    申请号：US12740648

    申请日：2008-11-04

    申请人： Morten Karsdal ,  Per Qvist ,  Natasha Barascuk

    发明人： Morten Karsdal ,  Per Qvist ,  Natasha Barascuk

    IPC分类号： G01N31/00 ,  G01N33/53 ,  C12Q1/37 ,  C07K14/775 ,  G01N33/542

    CPC分类号： G01N33/6878 ,  C07K14/77 ,  C07K14/775 ,  C07K14/78 ,  C12Q1/37 ,  G01N33/542 ,  G01N33/577 ,  G01N33/6893 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52

    摘要： A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

    摘要翻译： 一种用于定量肽片段的生物测定方法，其包含通过切割动脉粥样硬化斑块的蛋白质如lumican，versican，perlecan，核心蛋白聚糖，双糖链蛋白聚糖，III型胶原，CRP，ApoE或弹性蛋白的蛋白质形成的新表位。 所述方法包括使诸如尿液或血清的样品与抗原表位反应的抗体接触并确定所述免疫结合配偶体与所述样品中肽片段的结合水平。 该测定法预测心血管疾病事件的风险。

    ASSAY FOR A TYPE II COLLAGEN BIOMARKER
    54.
    发明申请
    ASSAY FOR A TYPE II COLLAGEN BIOMARKER 审中-公开
    一种II型胶原生物标记物的测定

    公开(公告)号：US20130260400A1

    公开(公告)日：2013-10-03

    申请号：US13825795

    申请日：2011-09-16

    申请人： Anne-Christine B. Jensen ,  Qi Liu ,  Jianxia Wang

    发明人： Anne-Christine B. Jensen ,  Qi Liu ,  Jianxia Wang

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6887 ,  C07K16/18 ,  G01N33/6878 ,  G01N2333/78 ,  G01N2800/105

    摘要： An assay for Type II collagen fragments in serum, plasma, or synovial fluid obtains a quantitative measure of the concentration of all protein fragments in a serum, plasma, or synovial fluid sample that are reactive with an antibody, or immunoreactive antibody fragment, having specific reactivity with a C-terminal epitope present in the amino acid sequence GPPGRDGAAG and lacking specific reactivity with an amino acid sequence comprising the amino acid sequence GPPGRDGAAGV, which may be Mab NB44-3C1 as produced by the cell line deposited in HPA Culture Collection Logistics Office with Accession Number 10091402.

    摘要翻译： 在血清，血浆或滑液中的II型胶原片段的测定法获得与抗体或免疫反应性抗体片段反应的血清，血浆或滑液样品中所有蛋白质片段的浓度的定量测量，所述抗体或免疫反应性抗体片段具有特异性 与存在于氨基酸序列GPPGRDGAAG中的C-末端表位的反应性，并且与包含氨基酸序列GPPGRDGAAGV的氨基酸序列缺乏特异性反应性，所述氨基酸序列可以是由存储在HPA培养物理处所的细胞系产生的Mab NB44-3C1 登录号10091402。